Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2026 ASCO GU
2026 ASCO GI
SUO 2025
SABCS 2025
ASH 2025
Calendar
View All
Topics
AI in Oncology
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
Case 2: Acquired Resistance After First-Line Osimertinib-Based Therapy in EGFR L858R–Mutant NSCLC
More From This Roundtable
Case 1: First-Line Therapy for EGFR-Mutant Metastatic NSCLC
Case 3: Perioperative Management of Resectable EGFR-Mutant NSCLC
Advertisement
Mar
10
Today In Oncology
Neoadjuvant Sacituzumab Govitecan Plus Perioperative Pembrolizumab in Muscle-Invasive Bladder Cancer
Prostate Cancer Does Taking ARPIs and Anticoagulants Together Raise Risks
FDA Releases Updated Guidance on Biosimilar Development
SABCS 2025: High-Level Review of Select Data
Addition of Axitinib to Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors
View More
Advertisement
